Previous 10 | Next 10 |
Halozyme Therapeutics, Inc. (HALO) Q2 2021 Earnings Conference Call August 09, 2021, 04:30 PM ET Company Participants Al Kildani - Vice President of Investor Relations and Corporate Communications Helen Torley - President and CEO Elaine Sun - CFO Conference Call Participants Charles Duncan - ...
Halozyme Reports Second Quarter 2021 Results - Raising 2021 Revenue Guidance to $425-$445 Million from $375-$395 Million, GAAP Earnings Per Share Guidance to $1.55-$1.70 from $1.25-$1.40 and Non-GAAP Earnings per Share Guidance to $1.85-$2.00 from $1.55-$1.70 - - Second Quar...
Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference PR Newswire SAN DIEGO , July 30, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun , senior vice president and chief financial officer, wi...
Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , July 27, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2021 on ...
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse - Janssen's DARZALEX FASPRO® Now the F...
Michael Vi/iStock Editorial via Getty Images Johnson & Johnson's (JNJ) Janssen division received two European Commission ("EC") marketing authorizations for Darzalex SC, a subcutaneous formulation of Darzalex (daratumumab). The first is for Darzalex SC in combination with Velcade (bo...
Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma - Janssen received European approval for DARZALEX® (daratumu...
Halozyme’s drug delivery technology provides the opportunity to administer large volume subcutaneous injections that may enable dosing intervals of every three months and up to six months or longer for ViiV’s pipeline of HIV medicines ViiV Healthcare, the g...
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives exclu...
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV Halozyme's drug delivery technology provides the opportunity to administer large volume subcuta...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...